Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on August 13, 2025
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
GlobeNewswire
·
August 13, 2025
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
GlobeNewswire
·
August 13, 2025
PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic …
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the …
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
August 13, 2025
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance …
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 13, 2025
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in …
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
GlobeNewswire
·
August 13, 2025
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA …
On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours
GlobeNewswire
·
August 13, 2025
RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such …
Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to …
Tilray Medical stringe una partnership strategica in Italia per rendere più accessibili gli estratti di cannabis terapeutica
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, una divisione di Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) e leader mondiale nel settore della cannabis terapeutica, impegnata a rafforzare l'alleanza terapeutica tra pazienti e …
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
GlobeNewswire
·
August 13, 2025
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) …
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
GlobeNewswire
·
August 13, 2025
First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of …
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
GlobeNewswire
·
August 13, 2025
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 13, 2025
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to …
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
GlobeNewswire
·
August 13, 2025
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research …
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
GlobeNewswire
·
August 13, 2025
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO …
Vireo Growth Inc. Announces Second Quarter 2025 Results
GlobeNewswire
·
August 13, 2025
– Q2 GAAP revenue of $48.1 million increased 91% year-over-year, driven by recently-closed merger transactions – – Q2 pro forma financial results were in line with management’s previously communicated expectations – – Recent $153 million refinancing …
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
GlobeNewswire
·
August 13, 2025
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre- …
Immatics Announces Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 13, 2025
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase …
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC) Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025 …
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 13, 2025
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing …